ABSTRACT
The pneumococcal heptavalent conjugate vaccine protects children aged less than 2 years old from invasive pneumococcal disease (IPD). Efficacy is 89-93% in the US population and 71-86% in European studies. The vaccine confers active immunization against the main serotypes causing IPD (4, 6B, 9V, 14, 18C, 19F y 23F). We describe 2 children who presented with pneumococcal meningitis caused by nonvaccine serotypes. As a result of the widespread use of the heptavalent vaccine, there may be a shift in the serotypes causing IPD.
Subject(s)
Meningitis, Pneumococcal/microbiology , Meningococcal Vaccines , Pneumococcal Vaccines , Streptococcus pneumoniae/classification , Female , Heptavalent Pneumococcal Conjugate Vaccine , Humans , Infant , Male , Serotyping , Vaccines, ConjugateABSTRACT
La vacuna conjugada heptavalente protege a niños de menos de 2 años de la enfermedad neumocócica invasiva (ENI) en el 89-93 % en población estadounidense y en el 71-86 % en población europea. Confiere una inmunización activa frente a los serotipos mayoritariamente causantes de ENI (4, 6B, 9V, 14, 18C, 19F y 23F). Presentamos 2 casos de meningitis neumocócica por serotipos no vacunales. Es posible que haya un desplazamiento de serotipos causantes de ENI, como consecuencia de la generalización de la vacuna heptavalente
The pneumococcal heptavalent conjugate vaccine protects children aged less than 2 years old from invasive pneumococcal disease (IPD). Efficacy is 89-93 % in the US population and 71-86 % in European studies. The vaccine confers active immunization against the main serotypes causing IPD (4, 6B, 9V, 14, 18C, 19F y 23F). We describe 2 children who presented with pneumococcal meningitis caused by nonvaccine serotypes. As a result of the widespread use of the heptavalent vaccine, there may be a shift in the serotypes causing IPD
